Farm Comunitarios. 2024 Apr 11;16(2):43-45. doi: 10.33620/FC.2173-9218.(2024).11

Probable pharmacological interaction between sulfonylurea and beta-blocker in a patient with DM-II. A case report

Centeno-Hoil G1, Ramírez-Camacho MA1, Zapata-Escalante PL1, Arcos-Díaz A2, Soberanis-Monsreal LA3, Arana-Argáez VE4
1. Drug Information Center and Clinical Pharmacy, Faculty of Chemistry, Universidad Autónoma de Yucatán, Yucatán (Mexico) 2. Pharmacovigilance institutional center, High Specialty Hospital of the Yucatan Peninsula, Yucatán (Mexico) 3. Clinical Pharmacy, Hospital. High Specialty Regional of the Yucatán Peninsula, Yucatán (Mexico) 4. Pharmacology Laboratory, Faculty of Chemistry, Universidad Autónoma de Yucatán, Yucatán (Mexico)
Centeno-Hoil G, Ramírez-Camacho MA, Zapata-Escalante PL, Arcos-Díaz A, Soberanis-Monsreal LA, Arana-Argáez VE. Probable pharmacological interaction between sulfonylurea and beta-blocker in a patient with DM-II. A case report. Farm Comunitarios. 2024 Apr 11;16(2):43-45. doi: 10.33620/FC.2173-9218.(2024).11
Abstract : 

The study presents the case of a 47-year-old woman with type 2 diabetes (T2D), hypertension and anemia, treated with metformin, glyburide, metoprolol, and iron/folic acid. A drug interaction was identified between glyburide and metoprolol, causing symptoms of hypoglycemia in the afternoon. Evaluation using Horn’s Drug Interaction Probability Scale (DIPS) suggested a probable interaction. Pharmacokinetic analysis revealed that the time at which the maximum concentrations of both drugs were reached coincided with the onset of symptoms. A new medication schedule was implemented which resolved the symptoms. The drug interaction was attributed to the blockade of adrenergic effects by metoprolol, compromising the ability to counteract the action of insulin released by glybenclamide. The importance of surveillance, informed decision-making and the implementation of preventive strategies is highlighted to ensure the safety and effectiveness of pharmacological treatment in patients with specific clinical conditions, such as T2D and concomitant cardiovascular diseases.

Editor: © SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. 
Copyright© SEFAC. Sociedad Española de Farmacia Clínica, Familiar y Comunitaria. This article is available from url https://www.farmaceuticoscomunitarios.org/. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/

Share

-

Manual for authors

Journal Information